NET PROFIT (x1000 EUR)
EMPLOYEES
NEOGAP Therapeutics AB
Closing information (x1000 EUR)
| Closing information | 2023/12 | 2022/12 | 2021/12 |
| Turnover |
0
|
0
|
0 |
| Financial expenses |
22
|
115
|
137 |
| Earnings before taxes |
-1,031
|
-5,440
|
-988 |
| EBITDA |
-492
|
-231
|
-877 |
| Total assets |
11,009
|
5,713
|
12,169 |
| Current assets |
5,056
|
2,251
|
4,825 |
| Current liabilities |
1,812
|
368
|
435 |
| Equity capital |
4,375
|
537
|
6,503 |
| - share capital |
12
|
7
|
5 |
| Employees (average) |
14
|
14
|
13 |
Financial ratios
| Fiscal year | 2023/12 | 2022/12 | 2021/12 |
| Solvency |
39.7%
|
9.4%
|
53.4% |
| Turnover per employee |
0
|
0
|
0 |
| Profit as a percentage of turnover | |||
| Return on assets (ROA) |
-9.2%
|
-93.2%
|
-7.0% |
| Current ratio |
279.0%
|
611.7%
|
1109.2% |
| Return on equity (ROE) |
-23.6%
|
-1013.0%
|
-15.2% |
| Change turnover |
0
|
0
|
0 |
| Change turnover % | |||
| Chg. No. of employees |
0
|
1
|
3 |
| Chg. No. of employees % |
0%
|
8%
|
30% |
Total value of public sale
| Fiscal year | 2023/12 | 2022/12 | 2021/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.